Metraipolis › archive › dc_a2d5fdec2fe2

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity — Europe PMC PMID:42288516

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42288516
DOI: 10.1038/s41467-[numero omesso]-5
License (as archived): solo-consultazione
Archived: 2026-10-31T12:25:04.168Z
SHA-256 of the archived text: 0abf0fb6d25467792ce61e54d9dcac83d46dc9d8195c03936541713d6ddc9c2c
Stable URL of this page: https://metraipolis.com/documento/dc_a2d5fdec2fe2

How to cite

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity — Europe PMC PMID:42288516 — Europe PMC (en), https://europepmc.org/article/MED/42288516 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a2d5fdec2fe2 (Metraipolis archive dc_a2d5fdec2fe2, sha256 0abf0fb6d25467792ce61e54d9dcac83d46dc9d8195c03936541713d6ddc9c2c)

BibTeX

@misc{dca2d5fdec2fe2,
  title = {The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity — Europe PMC PMID:42288516},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42288516},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a2d5fdec2fe2; sha256 0abf0fb6d25467792ce61e54d9dcac83d46dc9d8195c03936541713d6ddc9c2c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42288516. Agents can read the archived copy with the MCP tool read_document.